Outcome of Board Meeting
Our Board of Directors at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Nine Months ended 31-12-2017. The Stand-alone and Consolidated unaudited financial results for the Quarter / Nine Months ended December 31, 2017, along with the Limited Review Reports, are attached. The Board also declared an Interim Dividend of Rs. 5/- Per Share for FY 2017-18, and fixed 16-02-2018 as record... Board Meeting To Be Held On 03-02-2018
Please refer to our letter dated January 27, 2018, intimating to you that a meeting of Board of Directors of the Company will be held on Saturday, the 3rd February 2018, at the Corporate Office of the Company, inter alia, to consider and approve Unaudited Stand-alone as well as Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2017.... Closure of Trading Window
We have intimated to you by a separate letter about the meeting of the Board of Directors scheduled to be held on Saturday, February 03, 2018 to consider and approve the (Stand-alone & Consolidated) unaudited financial results for the quarter / nine months ended December 31, 2017. In this regard, we would like to inform you that pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, and in accordance with the... Board Meeting To Be Held On 03-02-2018
Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of Board of Directors of the Company will be held on Saturday, the 3rd February 2018, at the Corporate Office of the Company, inter alia, to consider and approve Unaudited Stand-alone as well as Consolidated Financial Results of the Company for the quarter / nine months ended December 31, 2017.... Statement Of Investor Grievances For The Quarter Ended 31-12-2017
We enclose the statement of Investor grievances for the quarter ended December 31, 2017. Shareholding for the Period Ended December 31, 2017
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly Click here Thyrocare launches tuberculosis testing facility FocusTB
Diagnostics services provider Thyrocare today announced the launch of FocusTB, its affordable brand focusing on TB diagnostics. With the launch of our TB offering, we hope to make a fundamental and... Press Release / Media Release
We enclose a copy of press release issued by us today announcing launch of Focus TB, the brand for Tuberculosis Testing Services at an affordable cost. Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are filing herewith a transcript of the conference call held to discuss the Company's unaudited financial results (stand-alone and consolidated) for Quarter/Half Year ended September 30, 2017, on Tuesday, December 12, 2017 at 2.30 P.M. local time. Dr. Velumani A., Ph.D., CEO, Mr. A. Sundararaju, CFO and Mr. Sachin Salvi, GM-Finance, represented the Company. Broker's Call
JMFLThyrocare Tech (Buy)CMP: 657.45Target: 920In 2QFY18, Thyrocare's revenue/EBITDA/adjusted PAT grew 13 per cent/ 18 per cent/ 40 per cent y-o-y to 88 crore/ 35.7 crore/ 24.8 crore, respectively....